Is S1800a data sufficient to adopt ramucirumab + pembrolizumab in your clinical practice immediately, or is phase 3 data needed?
Answer from: Medical Oncologist at Academic Institution
Personally, while I think these data are compelling, I do not think it will lead me to adopt this regimen immediately. My slight bias in this direction could be changed by three things: (1) read-out of several ongoing trials testing ICI-VEGF combinations in NSCLC in various settings; (2) a trial com...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The overall survival benefit seen in S1800A was significant in the phase II trial and may be appropriate for some patients. A phase 3 confirmatory trial would ideally be done.
Answer from: Medical Oncologist at Academic Institution
In my view, the data seem compelling though, I feel that a phase III trial is needed to confirm the benefit observed in the phase II trial. If ramucirumab + pembrolizumab is available for clinical use, I would discuss the regimen with patients who I think may benefit from the treatment.
Answer from: Medical Oncologist at Community Practice
Financially too toxic and it’s a me-too drug versus biosimilars.
In my opinion, the study is a waste looking at this combination and not using biosimilars.